Unknown statusInterventionalPhase 2Updated Jan 7, 2010
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision | NCT01053858 | Trialant
CompletedInterventionalNot ApplicableUpdated Jan 22, 2010
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision
ClinicalTrials.gov ID
NCT01053858
Lead Sponsor
Hallym University Medical CenterOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Not Applicable
Enrollment
38Actual
Last Update Posted
Jan 22, 2010Estimated
Start Date
Jan 2008
Primary Completion Date
Jan 2009Actual
Completion Date
Jan 2010Actual
Brief Summary
To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.
Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity
intravitreal injection
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion
Exclusion Criteria:
previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
neovascularization on the disc or elsewhere or rubeosis